Johannes Lübke

Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin

Abstract Advanced systemic mastocytosis (AdvSM) is driven by KIT D816V in approximately 95% of cases. Accurate assessment and prediction of clinical course and disease outcome before and during treatment with the KIT inhibitors midostaurin and avapritinib may facilitate optimizat...

Two cases of an imatinib-sensitive PRKG2::PDGFRA-positive chronic myeloid neoplasm with basophilia

The clinical and morphological phenotype of myeloid/lymphoid neoplasms with tyrosine kinase (TK) gene fusions (MLN-TK) is influenced by both the TK and the partner gene [ 1 ]. Here, we report on two patients with an initial diagnosis of a chronic myeloid neoplasm with prominent b...